## Anna Ehinger

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2024412/publications.pdf

Version: 2024-02-01

56 papers 4,589 citations

236925 25 h-index 243625 44 g-index

62 all docs

62 docs citations

62 times ranked 8753 citing authors

#	Article	IF	CITATIONS
1	Pan-cancer analysis of whole genomes. Nature, 2020, 578, 82-93.	27.8	1,966
2	Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes. Science, 2014, 345, 1251343.	12.6	348
3	Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer. ELife, 2014, 3, .	6.0	318
4	Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study. Nature Medicine, 2019, 25, 1526-1533.	30.7	218
5	The path to a better biomarker: application of a risk management framework for the implementation of PDâ€L1 and TILs as immunoâ€oncology biomarkers in breast cancer clinical trials and daily practice. Journal of Pathology, 2020, 250, 667-684.	4.5	142
6	Spatial deconvolution of HER2-positive breast cancer delineates tumor-associated cell type interactions. Nature Communications, 2021, 12, 6012.	12.8	140
7	The Sweden Cancerome Analysis Network - Breast (SCAN-B) Initiative: a large-scale multicenter infrastructure towards implementation of breast cancer genomic analyses in the clinical routine. Genome Medicine, 2015, 7, 20.	8.2	129
8	The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group. Npj Breast Cancer, 2021, 7, 150.	5.2	112
9	Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. Npj Breast Cancer, 2020, 6, 17.	5.2	106
10	Clinical Value of RNA Sequencing–Based Classifiers for Prediction of the Five Conventional Breast Cancer Biomarkers: A Report From the Population-Based Multicenter Sweden Cancerome Analysis Network—Breast Initiative. JCO Precision Oncology, 2018, 2, 1-18.	3.0	101
11	Processed pseudogenes acquired somatically during cancer development. Nature Communications, 2014, 5, 3644.	12.8	86
12	Refinement of breast cancer molecular classification by miRNA expression profiles. BMC Genomics, 2019, 20, 503.	2.8	75
13	Analytical validation of a standardised scoring protocol for Ki67 immunohistochemistry on breast cancer excision whole sections: an international multicentre collaboration. Histopathology, 2019, 75, 225-235.	2.9	74
14	G protein-coupled estrogen receptor 1 (GPER, GPR 30) in normal human endometrium and early pregnancy decidua. Molecular Human Reproduction, 2010, 16, 743-751.	2.8	55
15	Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple negative breast cancers. Nature Communications, 2020, 11, 3747.	12.8	53
16	Expression of HIF- $1\hat{1}\pm$ is related to a poor prognosis and tamoxifen resistance in contralateral breast cancer. PLoS ONE, 2019, 14, e0226150.	2.5	52
17	Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013. Acta Oncológica, 2017, 56, 68-74.	1.8	51
18	The G protein-coupled estrogen receptor 1 (GPER/GPR30) does not predict survival in patients with ovarian cancer. Journal of Ovarian Research, 2012, 5, 9.	3.0	47

#	Article	IF	CITATIONS
19	Cross comparison and prognostic assessment of breast cancer multigene signatures in a large population-based contemporary clinical series. Scientific Reports, 2019, 9, 12184.	3.3	39
20	Differential localization and expression of urokinase plasminogen activator (uPA), its receptor (uPAR), and its inhibitor (PAI-1) mRNA and protein in endometrial tissue during the menstrual cycle. Molecular Human Reproduction, 2004, 10, 655-663.	2.8	38
21	Prediction of Lymph Node Metastasis in Breast Cancer by Gene Expression and Clinicopathological Models: Development and Validation within a Population-Based Cohort. Clinical Cancer Research, 2019, 25, 6368-6381.	7.0	37
22	The mutational landscape of the <scp>SCAN</scp> â€B realâ€world primary breast cancer transcriptome. EMBO Molecular Medicine, 2020, 12, e12118.	6.9	36
23	Minimizing inequality in access to precision medicine in breast cancer by real-time population-based molecular analysis in the SCAN-B initiative. British Journal of Surgery, 2018, 105, e158-e168.	0.3	32
24	Variability in Breast Cancer Biomarker Assessment and the Effect on Oncological Treatment Decisions: A Nationwide 5-Year Population-Based Study. Cancers, 2021, 13, 1166.	3.7	31
25	Changing clinical presentation of angiosarcomas after breast cancer: from late tumors in edematous arms to earlier tumors on the thoracic wall. Breast Cancer Research and Treatment, 2010, 122, 883-887.	2.5	30
26	Contralateral breast cancer can represent a metastatic spread of the first primary tumor: determination of clonal relationship between contralateral breast cancers using next-generation whole genome sequencing. Breast Cancer Research, 2015, 17, 102.	5.0	30
27	An Open-Source, Automated Tumor-Infiltrating Lymphocyte Algorithm for Prognosis in Triple-Negative Breast Cancer. Clinical Cancer Research, 2021, 27, 5557-5565.	7.0	26
28	Prognostic implications of the expression levels of different immunoglobulin heavy chain-encoding RNAs in early breast cancer. Npj Breast Cancer, 2020, 6, 28.	5.2	25
29	Agreement between molecular subtyping and surrogate subtype classification: a contemporary population-based study of ER-positive/HER2-negative primary breast cancer. Breast Cancer Research and Treatment, 2019, 178, 459-467.	2.5	23
30	Molecular analyses of triple-negative breast cancer in the young and elderly. Breast Cancer Research, 2021, 23, 20.	5.0	23
31	Preexisting Somatic Mutations of Estrogen Receptor Alpha ( <i>ESR1</i> ) in Early-Stage Primary Breast Cancer. JNCI Cancer Spectrum, 2021, 5, pkab028.	2.9	20
32	Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer. Breast Cancer Research, 2021, 23, 26.	5.0	19
33	Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study. Modern Pathology, 2022, 35, 1362-1369.	5.5	18
34	Histamine uptake by human endometrial cells expressing the organic cation transporter EMT and the vesicular monoamine transporter-2. Molecular Human Reproduction, 2006, 12, 483-489.	2.8	13
35	Prior Adjuvant Tamoxifen Treatment in Breast Cancer Is Linked to Increased AIB1 and HER2 Expression in Metachronous Contralateral Breast Cancer. PLoS ONE, 2016, 11, e0150977.	2.5	9
36	Prognosis, stage and oestrogen receptor status of contralateral breast cancer in relation to characteristics of the first tumour, prior endocrine treatment and radiotherapy. European Journal of Cancer, 2015, 51, 2304-2313.	2.8	8

#	Article	IF	Citations
37	Breast metastases from pancreatic and ovarian carcinoma. Diagnostic Cytopathology, 1999, 21, 154-155.	1.0	7
38	Difficulties in diagnostics of lung tumours in biopsies: an interpathologist concordance study evaluating the international diagnostic guidelines. Journal of Clinical Pathology, 2022, 75, 302-309.	2.0	7
39	The Prognostic Role of Intratumoral Stromal Content in Lobular Breast Cancer. Cancers, 2022, 14, 941.	3.7	5
40	Stability of oestrogen and progesterone receptor antigenicity in formalinâ€fixed paraffinâ€embedded breast cancer tissue over time. Apmis, 2018, 126, 746-754.	2.0	4
41	Development of Training Materials for Pathologists to Provide Machine Learning Validation Data of Tumor-Infiltrating Lymphocytes in Breast Cancer. Cancers, 2022, 14, 2467.	3.7	4
42	Acute pancreatitis evoked by small-cell lung carcinoma metastases and detected by endoscopic ultrasound. Endoscopy, 2012, 44, E45-E46.	1.8	3
43	Paracrine Stimulation of Capillary Endothelial Cell Migration by Endometrial Tissue Involves Epidermal Growth Factor and Is Mediated Via Up-Regulation of the Urokinase Plasminogen Activator Receptor. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 1724-1730.	3.6	3
44	Defining the mutational landscape of 3,217 primary breast cancer transcriptomes through large-scale RNA-seq within the Sweden Cancerome Analysis Network: Breast Project (SCAN-B; NCT03430492) Journal of Clinical Oncology, 2020, 38, 518-518.	1.6	2
45	Abstract P4-09-03: On the development and clinical value of RNA-sequencing-based classifiers for prediction of the five conventional breast cancer biomarkers: A report from the population-based multicenter SCAN-B study. , 2018, , .		1
46	Abstract CT074: Pre-existing ESR1 mutations in early-stage primary breast cancer predict failure of endocrine therapy and poor survival., 2020, , .		1
47	Abstract P6-08-43: Histological grade provides significant prognostic information in the discrimination between luminal A-like and luminal B-like HER-2 normal subtypes of breast cancer according to St Gallen 2013. , 2015, , .		0
48	Abstract P1-07-17: The SCAN-B study: 5-year summary of a large-scale population-based prospective breast cancer translational genomics platform covering a wide geography of Sweden (NCT02306096). , $2017,$		0
49	Abstract P2-02-09: Breast cancer subtype distribution and circulating tumor DNA in response to neoadjuvant chemotherapy: Experiences from a preoperative cohort within SCAN-B., 2018,,.		0
50	Abstract P2-03-01: Analytical validation of a standardized scoring protocol for Ki67 assessed on breast excision whole sections: An international multicenter collaboration., 2018,,.		0
51	Abstract P1-06-01: Putting multigene signatures to the test: Prognostic assessment in population-based contemporary clinical breast cancer. , 2018, , .		0
52	Abstract P3-02-02: Concordance between immunohistochemical and gene-expression based subtyping of early breast cancer using core needle biopsies and surgical specimens - experices from SCAN-B., 2018,,.		0
53	Abstract P1-18-10: Preoperative treatment of HER2-positive breast cancer in South Sweden. A retrospective, comprehensive survey of neo-adjuvant treated HER2-positve breast cancer in the SCAN-B project 2010-2017., 2020,,.		0
54	Abstract P5-02-01: Analytical validation and prognostic potential of an automated digital scoring protocol for Ki67: An International Ki67 Working Group study. , 2020, , .		0

## Anna Ehinger

#	Article	IF	CITATIONS
55	Abstract P2-08-11: How reliable are biomarkers assessed on a core needle biopsy? A study of paired core needle biopsies and surgical specimens in early breast cancer. Cancer Research, 2022, 82, P2-08-11-P2-08-11.	0.9	0
56	Abstract 460: Tools for collecting pathologist annotations and understanding interobserver variability. Cancer Research, 2022, 82, 460-460.	0.9	0